Scientific Programme

Session D.01: Treatment and Prevention
Thursday 4 May 2017 08:30 - 10:25

Chairs: Stuart Adler & Suresh Boppana

08:30 - 09:10
Keynote Lecture: CMV drug development: current landscape, challenges and opportunities Veronica Miller, Executive Director Forum for Collaborative Research, Washington DC, United States of America
09:10 - 09:25
Live-CMV vaccines lacking viral MHC I homologs are attenuated in guinea pigs but confer sterilizing immunity against congenital CMV transmission Mark Schleiss, Division Director, Pediatric Infectious Diseases Uiversity of Minnesota, Minneapolis, United States of America
09:25 - 09:40
Active evolution of memory B-cells specific for viral gH/gL/pUL128-131 pentameric complex in healthy subjects with silent human cytomegalovirus infection Tong-Ming Fu Merck Sharp and Dohme Company, West Point, United States of America
09:40 - 09:55
The breadth of synthetic long peptide vaccine-induced CD8+ T cell responses determines the efficacy against mouse cytomegalovirus infection Eleni Panagioti LUMC, Leiden, Netherlands
09:55 - 10:10
Novel antivirals for the prevention and treatment of congenital CMV Stuart Hamilton Virology Research Laboratory, SEALS Microbiology, Sydney, Australia
10:10 - 10:25
A CMV vaccine based on non-replicating lymphocytic choriomeningitis virus vectors expressing gB and pp65 is safe and immunogenic in man Anders Lilja Hookipa Biotech AG, Vienna, Austria
CMV 2017: the 6th International congenital CMV conference/16th International CMV/betaherpesvirus workshop in 2017<